Vibrant Therapeutics ("Vibrant"), a clinical-stage biotechnology company developing next-generation intelligent therapeutics, today announced $61 million in new financing. The financing includes new ...
The presented findings are important for the field of cell-cycle control. They provide new insights into the origin of cell size variability in budding yeast. The strength of evidence is solid.
The Greater Scranton YMCA received a grant award of $2,000 from the BK5K Youth Fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback